COMP <GO>
DVA vs UNH // EV/EBITDA & P/E VALUATION
DaVita Inc. (NYSE) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: DVA 10
— UNH 5
▲ EV/EBITDA & P/E VALUATION LEADER: DVA
LAST: $187.50 (-3.01%) • MKT CAP: $12.33B
valuation
7.3x
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
valuation
16.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DVA VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DVA | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 88.57% | -47.57 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 29.20% | 11.47% | +17.73 | DVA | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 7.3x | 16.4x | -9.15 | DVA | /valuation <GO> |
| Free Cash Flow Yield | 10.63% | 6.48% | +4.15 | DVA | /fcf-yield <GO> |
| Operating Margin | 15.00% | 4.82% | +10.18 | DVA | /operating-margins <GO> |
| Net Profit Margin | 7.90% | 3.14% | +4.76 | DVA | /net-margins <GO> |
| Revenue Growth (YoY) | 6.50% | 6.46% | +0.04 | DVA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.66 | 3.12 | -1.46 | UNH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | DVA | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 6.74% | -0.04 | DVA | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.3 | 56.0 | -1.72 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 0.33 | +0.62 | DVA | /macro-sensitivity <GO> |
| Forward P/E Multiple | 10.6x | 17.1x | -6.49 | DVA | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $12.33B | $364.66B | -$352.33B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DVA REV | UNH REV | DVA GROSS % | UNH GROSS % | DVA FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $13.64B | $447.57B | 44.0% | 88.7% | $1.31B | $16.07B |
| FY 2024 | $12.82B | $400.28B | 44.0% | 88.3% | $1.47B | $20.70B |
| FY 2023 | $12.14B | $371.62B | 44.0% | 89.6% | $1.51B | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DVA // BETA 0.95
UNH // BETA 0.33